In the phase III trials of pembrolizumab monotherapy among patients with PD‐L1 expression in at least 50% of the tumor cells, the median PFS was 309 days in the KEYNOTE‐024 study and 210 days in the KEYNOTE‐042 study.4, 13. Here, CD274 is linked to neoplasm.